ArticleMicroorganisms2021
Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance.
Open access · goldAbstract read
In one paragraph
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 33 citations in OpenAlex.
- Review
- Predicting the evolution and persistence of COVID-19 using context-dependent polymorphisms.Scientific reports · 2026Article
- Characterization of the Cross-Resistance of SARS-CoV‑2 Main Protease Inhibitors, Ibuzatrelvir, Ensitrelvir, and Nirmatrelvir.ACS pharmacology & translational science · 2026Article
- Role of remdesivir for the treatment of COVID-19 in patients with hematologic malignancy-A narrative review and expert opinion.European journal of clinical investigation · 2025Review
- Dual-Site Inhibition of SARS-CoV-2 RNA-Dependent RNA Polymerase by Small Molecules Able to Block Viral Replication Identified through a Computer-Aided Drug Discovery Approach.ACS infectious diseases · 2025Article
- High Concordance Between SYBR Green and TaqMan PCR for SARS-CoV-2 Detection in Nasopharyngeal and Saliva Samples.Viruses · 2025Article
- Evolution of Antiviral Drug Resistance in SARS-CoV-2.Viruses · 2025Review
- The impact of remdesivir on SARS-CoV-2 evolution in vivo.JCI insight · 2025Article
- Article
- Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate.Antimicrobial agents and chemotherapy · 2024Article
- BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.Antimicrobial agents and chemotherapy · 2024Article
- Article
- Alterations of SARS-CoV-2 Evolutionary Dynamics by Pharmaceutical Factors.Infectious diseases & immunity · 2024Review
- Comparison of Circulating Variants during the Beginning, Middle and the End of the 4th Wave of COVID-19 in Tehran Province, Iran in 2021.Iranian journal of public health · 2023Article
- Bacterial Proteases as Potentially Exploitable Modulators of SARS-CoV-2 Infection: Logic from the Literature, Informatics, and Inspiration from the Dog.Biotech (Basel (Switzerland)) · 2023Article
- Atovaquone and Pibrentasvir Inhibit the SARS-CoV-2 Endoribonuclease and Restrict Infection In Vitro but Not In Vivo.Viruses · 2023Article
- Article
- MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases.Current opinion in virology · 2023Review
- Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model.Journal of medical virology · 2023Article
- Recent advances in small-molecular therapeutics for COVID-19.Precision clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 4 institutions in 1 country.
Alfredo MariApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0002-3871-088X
Tim RoloffApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
Madlen StangeApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0002-4559-2535
Kirstine K SøgaardApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
Erblin AsllanajSIB Swiss Institute of Bioinformatics, 4053-4056 Basel, Switzerland.
Gerardo TaurielloSIB Swiss Institute of Bioinformatics, 4053-4056 Basel, Switzerland.ORCID 0000-0002-5921-7007
Leila Tamara AlexanderSIB Swiss Institute of Bioinformatics, 4053-4056 Basel, Switzerland.ORCID 0000-0002-7594-2110
Michael SchweitzerApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
Karoline LeuzingerClinical Virology, University Hospital Basel, 4031 Basel, Switzerland.
Alexander GenschApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
Aurélien E MartinezInfectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.ORCID 0000-0001-9709-0644
Julia BielickiPediatric Infectious Diseases, University of Basel Children's Hospital, 4056 Basel, Switzerland.
Hans ParggerIntensive Care Medicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0002-1234-7568
Martin SiegemundIntensive Care Medicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0002-2013-4140
Christian H NickelEmergency Medicine, University Hospital Basel, 4031 Basel, Switzerland.
Roland BingisserEmergency Medicine, University Hospital Basel, 4031 Basel, Switzerland.
Michael OsthoffInternal Medicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0001-5439-957X
Stefano BassettiInternal Medicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0003-1729-1425
Parham SendiInfectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.ORCID 0000-0002-7347-6312
Manuel BattegayInfectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
Catia MarzoliniInfectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
Helena M B Seth-SmithApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0002-6082-5114
Torsten SchwedeSIB Swiss Institute of Bioinformatics, 4053-4056 Basel, Switzerland.ORCID 0000-0003-2715-335X
Hans H HirschClinical Virology, University Hospital Basel, 4031 Basel, Switzerland.
Adrian EgliApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0002-3564-8603
University of Basel · CHSIB Swiss Institute of Bioinformatics · CHUniversity Hospital of Basel · CHUniversity of Bern · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
A variety of antiviral treatments for COVID-19 have been investigated, involving many repurposed drugs. Currently, the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp, encoded by
Indexed as
diagnosticsevolutiongenome analysisremdesivirresistanceRNA dependent RNA polymeraseSARS-CoV-2surveillance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.